National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pegylated interferon alfa
A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:PEG-interferon alfa
Abbreviation:PEG-IFN-a



Previous:pegaspargase, PEGASYS, pegfilgrastim, pegylated anti-GFR antibody fragment, pegylated granulocyte colony stimulating factor MAXY-G34
Next:pegylated irinotecan NKTR 102, pegylated liposomal doxorubicin hydrochloride, pelitrexol, pemetrexed disodium, Pen-Vee

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov